Metabolic syndrome
Drug research and approvals for metabolic syndrome: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 655 studies of metabolic syndrome are recruiting on ClinicalTrials.gov, and Health Canada has authorized 11 drug trials for it since 2013.
- Recruiting worldwide: 655
- Trials authorized in Canada: 11
- FDA orphan approvals: 0
- EU medicines: 0
Recruiting Now
Newest start dates first, of 655 recruiting on ClinicalTrials.gov ↗- Liver Steatosis in Pediatric CD PatientsNCT06206616 · Not reported · University of Palermo · starts Nov 1, 2027
- Regulating Together for Prader-Willi Syndrome: A Group Behavioral Therapy for Emotion DysregulationNCT07607730 · Not applicable · Children's Mercy Hospital Kansas City · starts Jan 1, 2027
- Symptoms of Polycystic Ovarian Syndrome Ameliorated by Keto-Adaptation PilotNCT07227363 · Not applicable · Ohio State University · starts Dec 1, 2026
- BRE-13: Mediterranean DietNCT07869355 · Not applicable · University of Illinois Chicago · starts Nov 11, 2026
- Fulvic Acid Supplementation and Metabolic SyndromeNCT07927283 · Not applicable · Arizona State University · starts Nov 6, 2026
- Asprosin and miRNA Expression in Young Women With Metabolic SyndromeNCT07917364 · Not reported · University of Applied Sciences in Nowy Targ · starts Nov 1, 2026
- Acute Effects of Ketone Monoester Co-ingestion With Dietary Protein on Whole-body Phenylalanine Oxidation,…NCT07884539 · Not applicable · McGill University · starts Oct 23, 2026
- Ketogenic Metabolic Therapy in Schizophrenia, Bipolar Disorder, Major Depressive Disorder: Deep Omic ProfilingNCT06748950 · Not applicable · Stanford University · starts Oct 19, 2026
- Pilot Study of Galantamine to Treat Metabolic Syndrome in People With Chronic Traumatic Spinal Cord Injury (SCI)NCT07625332 · Phase 2 / Phase 3 · Northwell Health · starts Oct 15, 2026
- Safety and Tolerability of Metformin and Naproxen for Cancer Prevention in Fanconi AnemiaNCT07901959 · Phase 1 · Rockefeller University · starts Oct 14, 2026
Trials Authorized in Canada
The 10 newest of 11; search them all in Canada trials| Jan 2, 2024 | A single center, phase 1, randomized, double-blind, placebo-controlled single and multiple ascending dose study to evaluate the safety, tolerability, and…INV-347 | INVERSAGO PHARMA INC | Closed |
| May 2, 2023 | A phase 2, randomized, double-blind, placebo-controlled, and open-label extension study of the efficacy, safety, and pharmacokinetics of three doses of inv-202…INV-202 | INVERSAGO PHARMA INC | Closed |
| Sep 6, 2022 | 12-month randomized, multicenter, double-blind, placebo-controlled phase 3 study to evaluate the safety and efficacy of daily subcutaneous metreleptin…METRELEPTIN FOR INJECTION | Chiesi Farmaceutici S.p.A. | Closed |
| Jan 19, 2022 | A phase 1b study to examine the pharmacokinetic and pharmacodynamic effects of inv-202 in subjects with metabolic syndrome as defined by hypertriglyceridemia,…INV-202 | INVERSAGO PHARMA INC | Ongoing |
| Jul 3, 2019 | Effect of vitamin d on reducing body fat and improving metabolic syndrome in the newfoundland population (open label)VITAMIN D3 | MEMORIAL UNIVERSITY | Pending |
| Feb 16, 2018 | Fecal microbial transplantation and fiber supplementation in subjects with obesity and metabolic syndromeFECAL MICROBIOTA FOR TRANSPLANTATION (FMT) | GOVERNORS OF THE UNIVERSITY OF ALBERTA | Closed |
| Mar 7, 2017 | A randomized phase 3 trial of metformin in patients initiating androgen deprivation therapy as prevention and intervention of metabolic syndrome: the prime…METFORMIN | CANADIAN UROLOGICAL ONCOLOGY GROUP | Closed |
| Nov 10, 2016 | A phase 2, double-blind, placebo-controlled, dose-ranging study to evaluate the safety and efficacy of pbi-4050 in type 2 diabetes mellitus patients with…PBI-4050 | PROMETIC PHARMA SMT LTD | Closed |
| Jun 6, 2016 | Transplantation of microbes of fecal origin for prevention and treatment of metabolic syndrome and non alchoholic fatty liver diseaseFECAL MICROBIAL TRANSPLANT | ST JOSEPHS HEALTHCARE | Ongoing |
| Jan 23, 2015 | A phase 2, single-arm, open-label study to evaluate the safety and tolerability of pbi-4050 in type 2 diabetes patients with metabolic syndromePBI-4050 | PROMETIC BIOSCIENCES INC | Closed |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA